Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026 ELEMENT-- Back to the Newsroom Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026 VANCOUVER, BC / ACCESS Newswire/ March 24, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") reports preliminary and unaudited financial results for its fourth quarter and year ended December 31, 2025. All figures are stated in Canadian dollars unless otherwise note ...

2026.03. 24 本文字数：2990，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 "十五五"规划纲要明确提出实施健康优先发展战略，并将生物制药列为新兴支柱产业，为跨国医药企 业参与"健康中国"建设提供了新机遇。 近日，"中国发展高层论坛2026年年会"（下称"年会"）召开。年会期间，国家卫健委和中央财经委等 有关部门均释放了深化医药卫生体制改革、促进医疗等重点领域科技创新、优化营商环境和加大对外 开放的积极信号。 多名与会跨国医药企业高管均积极回应，将扩大在华业务，加大在细胞疗法等前沿领域的本地化生产 能力，继续投资本地创新并加强创新合作。 在深度参与中国医药创新的过程中，这些跨国医药企业对中国医药创新生态也有更多期待：其一，优 化完善与创新相匹配的知识产权保护体系、价值认定和支付机制，为企业提供制度性激励；其二，以 临床需求为导向，推动市场和监管的关注点从产品创新转向系统性集成创新，加大中国在疾病治理和 创新方案上的输出能力，完善涵盖患者、医疗机构、国内外制药企业和科研院所、社会资本以及监管 部门等多方的医药创新生态。 跨国药企深化在华布局 据国家卫健委消息，22日，上述年会"谋划'十五五'国民健 ...

Sio Capital Management disclosed a new position in Organon (OGN 3.91%) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end.What happenedAccording to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Sio Capital Management established a new position in Organon (OGN 3.91%), purchasing 3,421,765 shares. The reported position value at quarter-end increased by $24.53 million as a result of the purchase.What else to knowThis is a new position for ...

Core Viewpoint - Orogen Royalties Inc. has announced the cancellation of its planned private placement but remains well-funded to pursue its project generation and royalty acquisition objectives [1][2]. Group 1: Company Strategy and Operations - The cancellation of the private placement does not impact the company's exploration and investment strategy [2]. - Orogen plans to conduct up to 16 partner-funded drill programs throughout 2026, totaling over 50,000 meters of drilling, aimed at advancing projects and increasing the likelihood of exploration discoveries [2]. - The company is actively pursuing several short-term acquisition opportunities that complement its existing portfolio [2]. Group 2: Company Profile - Orogen Royalties focuses on organic royalty creation and acquisitions of precious and base metal discoveries in western North America [3]. - The company's royalty portfolio includes a 2.0% NSR royalty on the Ermitaño gold and silver mine in Sonora, Mexico, operated by First Majestic Silver Corp [3]. - Orogen is well-financed with multiple projects currently being developed by joint venture partners [3].

Core Viewpoint - Orogen Royalties Inc. plans to raise up to $10 million through a non-brokered private placement of common shares priced at $3.46 each, aimed at funding exploration initiatives, potential royalty acquisitions, and enhancing working capital for growth [1] Group 1: Private Placement Details - The private placement will consist of issuing up to 2,890,274 common shares [1] - Proceeds will be directed towards generative exploration initiatives, potential royalty acquisitions, and strengthening working capital [1] - Certain directors and officers may participate in the private placement, which will be considered a related party transaction exempt from formal valuation and minority shareholder approval requirements [1] Group 2: Financial Terms and Conditions - A finder's fee of 5% cash may be paid for common shares sold to investors introduced by finders, subject to approval by the TSX Venture Exchange [1] - All common shares issued will be subject to a four-month hold period under applicable securities laws in Canada [1] - The company anticipates closing the private placement within three to four weeks, pending necessary regulatory approvals [1] Group 3: Company Overview - Orogen Royalties focuses on organic royalty creation and acquisitions in precious and base metals in western North America [1] - The company's royalty portfolio includes a 2.0% NSR royalty on the Ermitaño gold and silver mine in Sonora, Mexico, operated by First Majestic Silver Corp [1] - The company is well-financed with several projects actively being developed by joint venture partners [1]

STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered in ...

Core Insights - Organon & Co. announced positive findings from a pooled sub-analysis of its Phase 3 ADORING trials for VTAMA (tapinarof) cream, showing early and sustained improvements in sleep outcomes for pediatric patients with moderate to severe atopic dermatitis [1][4][8] Group 1: Clinical Trial Results - The analysis included 654 pediatric patients aged 2-17 years, demonstrating significant improvements in sleep-related outcomes as measured by the Patient-Oriented Eczema Measure (POEM) and Dermatology Family Impact (DFI) scores [10][12] - Improvements in POEM sleep subdomain scores were observed as early as week one in children aged 2-6 and 12-17, with benefits sustained through week eight [11] - DFI sleep subdomain scores showed significant improvement by week one in patients aged 12-15 and by week two in younger cohorts, reinforcing the treatment's positive impact on both patients and their families [12] Group 2: Market and Financial Context - Organon currently has a market capitalization of $1.90 billion [6] - Shares of Organon have gained 0.8% since the announcement, but have declined 22.6% over the past six months, contrasting with the industry's 6.3% growth and the S&P 500's 9.1% rise [3] - The atopic dermatitis drug market is projected to reach $17.21 billion by 2026, with a compound annual growth rate (CAGR) of 7.7% through 2032, driven by increasing disease prevalence and demand for effective treatments [13] Group 3: Strategic Implications - The positive data from the Phase 3 sub-analysis supports Organon's strategy to develop therapies that target impactful outcomes in chronic dermatologic conditions, which is expected to drive prescription growth and strengthen the dermatology segment [2][4] - The findings highlight VTAMA's differentiated value in atopic dermatitis, particularly in improving quality of life through sleep outcomes, which is a significant burden in pediatric patients [4][8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-K _____________________ | (Mark One) ☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | For the fiscal year ended December 31, 2025 | | | OR | | ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from ______ to ______ | | | Commission File No. 001-40235 | Organon & Co. (Exact n ...

Organon & Co. (NYSE:OGN) is among the 7 Oversold Pharma Stocks to Buy Now. Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% Organon & Co. (NYSE:OGN) is among the most oversold pharma stocks. TheFly reported on February 12 that OGN announced its fourth-quarter and full-year 2025 financial results. According to the report, for the full year, the company’s revenue totaled $6.2 billion, which represents a 3% decline both on a reported basis and in constant currency. Diluted earning ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dru. ...